Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy
Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study
Sponsor: Samsung Medical Center
This PHASE2 trial investigates Colo-rectal Cancer and is currently completed. Samsung Medical Center leads this study, which shows 10 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jul 2022 — Jul 2024 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Mar 2022 — Jul 2022 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
▶ Show 5 earlier versions
-
Jan 2021 — Mar 2022 [monthly]
Recruiting PHASE2
-
Jan 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Jun 2018 — Jan 2020 [monthly]
Recruiting PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Apr 2017 — Feb 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Samsung Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .